Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel-spore conjugate (cetuximab-targeted)
- Development stage
- Preclinical
- Lead developer
- SporeGen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Microbiome Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Paclitaxel-spore conjugate (cetuximab-targeted)** is a preclinical EGFR-targeted cytotoxic delivery construct developed by SporeGen for colorectal cancer. It uses killed recombinant *Bacillus subtilis* spores displaying streptavidin as a carrier for paclitaxel and biotinylated cetuximab. Cetuximab directs the spore-associated payload to EGFR-expressing tumor cells, including HT29 colon cancer cells, while paclitaxel stabilizes microtubules through tubulin binding, disrupting mitosis and inhibiting tumor-cell proliferation. In reported in-vitro work, the cetuximab-targeted spore construct increased delivery of paclitaxel to HT29 cells and showed greater antiproliferative activity than water-soluble paclitaxel.
- Other names
- Cetuximab-targeted Paclitaxel spore conjugatePaclitaxel-Spore Conjugatepaclitaxel-SA1-cetuximabpaclitaxel-SA-1-cetuximabpaclitaxel-SA 1-cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel-spore conjugate (cetuximab-targeted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel-spore conjugate (cetuximab-targeted).